[MODY type diabetes: overview and recent findings]

Author(s): Ben Khelifa S, Barboura I, Dandana A, Ferchichi S, Miled A

Abstract

We present an update of knowledge on diabetes MODY (maturity onset diabetes of the young), including the recent molecular discoveries, and new diagnostic strategies. Considerable progress has been made in understanding the different molecular abnormalities that cause MODY and the phenotypic consequences resulting therefrom. MODY diabetes is very heterogeneous and is the most common form of monogenic diabetes. Its distribution is worldwide. MODY is an autosomal dominant diabetes mellitus, nonketotic and occurs at an early age (usually before 25 years). To date, at least seven genes are associated with MODY, with frequencies that differ from one population to another. Both 2 and 3 subtypes predominate, while other subtypes (1, 4, 5, 6 and 7) concern only a few families. Since its discovery in the sixties, studies have succeeded to fully clarify the epidemiological, molecular and clinical diagnosis of each subtype, to provide better care for patients. However, the subject of MODY has not yet revealed all its secrets. Indeed, it remains to identify other genes that are associated with MODY X.

Similar Articles

Type 2 diabetes: principles of pathogenesis and therapy

Author(s): Stumvoll M, Goldstein BJ, van Haeften TW

Alternative therapies for type 2 diabetes

Author(s): Dey L, Attele AS, Yuan CS

Brussels, Belgium: International Diabetes Federation

Author(s): International Diabetes Federation

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

Author(s): Wild S, Roglic G, Green A, Sicree R, King H

Prevalence of diabetes in Pakistan

Author(s): Shera AS, Jawad F, Maqsood A

Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 53: 2504-2508

Author(s): Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, et al.

A narrative insight to maturity-onset diabetes of the young

Author(s): Kanwal SF, Fazal S, Muhammad Ismail, Nighat Naureen

HLA-A, -B, and -DR associations in type 1 diabetes mellitus with onset after age forty

Author(s): Pittman WB, Acton RT, Barger BO, Bell DS, Go RC, et al.

Latent autoimmune diabetes in adults (LADA) should be less latent

Author(s): Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, et al.

Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes

Author(s): Cervin C, Lyssenko V, Bakhtadze E, Lindholm E, Nilsson P, et al.

Genetics of type 2 diabetes

Author(s): Owen KR, McCarthy MI

The emerging genetic architecture of type 2 diabetes

Author(s): Doria A, Patti ME, Kahn CR

Genome-wide association studies in type 2 diabetes

Author(s): McCarthy MI, Zeggini E

Type 2 diabetes: new genes, new understanding

Author(s): Prokopenko I, McCarthy MI, Lindgren CM

Type 2 Diabetes Genetics: Beyond GWAS

Author(s): Sanghera DK, Blackett PR

A genome-wide association study identifies novel risk loci for type 2 diabetes

Author(s): Sladek R, Rocheleau G, Rung J, Dina C, Shen L, et al.

Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels

Author(s): Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, Saxena R, Voight BF, et al.

A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants

Author(s): Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, et al.

A variant in CDKAL1 influences insulin response and risk of type 2 diabetes

Author(s): Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, et al.

A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity

Author(s): Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, et al.

Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis

Author(s): Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, et al.

Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci

Author(s): Saxena R, Elbers CC, Guo Y, Peter I, Gaunt TR, et al.

Genetic variation near the hepatocyte nuclear factor-4 alpha gene predicts susceptibility to type 2 diabetes

Author(s): Silander K, Mohlke KL, Scott LJ, Peck EC, Hollstein P, et al.

Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution

Author(s): Helgason A, Pálsson S, Thorleifsson G, Grant SF, Emilsson V, et al.

Association of variants of transcription factor 7-like 2 (TCF7L2) with susceptibility to type 2 diabetes in the Dutch Breda cohort

Author(s): van Vliet-Ostaptchouk JV, Shiri-Sverdlov R, Zhernakova A, Strengman E, van Haeften TW, et al.

Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study

Author(s): van Hoek M, Dehghan A, Witteman JC, van Duijn CM, Uitterlinden AG, et al.

Genetic variations in the gene encoding TFAP2B are associated with type 2 diabetes mellitus

Author(s): Maeda S, Tsukada S, Kanazawa A, Sekine A, Tsunoda T, et al.

Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus

Author(s): Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, et al.

Inflammatory markers and risk of developing type 2 diabetes in women

Author(s): Hu FB, Meigs JB, Li TY, Rifai N, Manson JE

Therapy with oral antidiabetic drugs: applied pharmacogenetics

Author(s): Holstein A, Seeringer A, Kovacs P

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action

Author(s): Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, et al.

Pharmacogenetics of Anti-Diabetes Drugs

Author(s): Distefano JK, Watanabe RM

Pharmacogenetics of oral antidiabetic treatment

Author(s): Schroner Z, Javorsky M, Kozarova M, Tkac I

Genetic basis of type 2 diabetes mellitus: implications for therapy

Author(s): Wolford JK, Vozarova de Courten B